Publications by authors named "M Papoutsaki"
Real-world effectiveness and drug survival of guselkumab over a period of 3 years in moderate-to-severe plaque psoriasis, including difficult-to-treat areas.
Natalia Rompoti Theognosia Vergou Irene Stefanaki Charitomeni Vavouli Ioannis-Alexios Koumprentziotis Marina Papoutsaki
Int J Dermatol
October 2024
Article Synopsis
- Bimekizumab is a monoclonal antibody that targets interleukin-17A and interleukin-17F, proving to be very effective for treating chronic plaque psoriasis with a quick impact based on Randomized Controlled Trials (RCTs).
- A study in Athens involved 61 patients with moderate-to-severe psoriasis, revealing that a significant percentage achieved marked improvement (PASI75: 65.7%, PASI90: 45.7%, PASI100: 32.4%) after just 4 weeks and even higher rates after 16 weeks.
- The safety profile showed a few mild-to-moderate adverse events, including oral candidiasis, aligning with